27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- ViiV Healthcare, majority-owned by GlaxoSmithKline plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi, has announced an exclusive collaboration and license agreement with Shionogi & Co Ltd for S-365598 for use in ultra long-acting HIV regimens.
- S-365598 is a third-generation integrase strand transfer inhibitor with the potential for regimens with three months or longer dosing intervals.
- Under the agreement terms, ViiV Healthcare will make an upfront payment of £20 million to Shionogi, £15 million as milestone payments, and royalties on net sales.
- Shionogi will contribute to development costs up to an annual maximum.
- First-in-human trials are slated for 2023.
- Price Action: PFE stock is down 1.94% at $42.73, and GSK stock is down 1.31% at $38 during the market session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!